FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247199816> ?p ?o ?g. }

• W2247199816 abstract "e14512 Background: BNC105P is a novel anticancer agent that inhibits tubulin polymerization and acts as a VDA. BNC105P is a phosphorylated parent compound which rapidly becomes the active agent BNC105. BNC105 exhibits 100-fold specificity for activated endothelial cells compared to quiescent endothelial cells. Methods: BNC105P (2.1 to 18.9 mg/m2) was given IV over 10 min on day 1 and 8 every 21 days to patients (pts) with advanced solid tumors (ECOG 0–2) and adequate organ function. The objectives were to determine safety, tolerability, MTD and pharmacokinetics (PK). A pharmacodynamic response was evaluated using DCE-MRI with two baseline and two post dose assessments (3–6, 24 h). DLTs were determined during the first 21 days. Results: 9 pts (7 M; 2 F), median age 60 years have been enrolled with one pt each at 2.1 and 4.2 mg/m2. At 8.4 mg/m2, one pt experienced Grade 2 (Gr 2) mucositis and a switch to a ‘3+3’ design occurred. No DLTs have been observed in 3 pts at 12.6 mg/m2 and 1 pt at 18.9 mg/m2. Notable toxicity includes one episode of Gr 1 febrile episode possibly related to infusion, two episodes of Gr 1 fatigue and one Gr 1 rash. PK data of BNC105 indicates a linear increase in plasma AUC levels (Table) and plasma half life of < 0.5 h. Best observed responses were SD in 2/9 pts including one pt with mesothelioma (progression at entry) with SD up to week 22 (8.4 mg/m2). At doses ≥ 8.4 mg/m2, DCE-MRI images indicate changes in tumor perfusion post-dose. Two pts at 12.6 mg/m2 had a decrease in Ktrans values of 6 and 15 % compared to baseline. Conclusions: Pharmacodynamically active doses have been achieved with plasma drug levels correlating with active preclinical plasma exposure. To date, no excess toxicity has been observed at doses up to 18.9 mg/m2. [Table: see text] [Table: see text]" @default.
• W2247199816 created "2016-06-24" @default.
• W2247199816 creator A5004217603 @default.
• W2247199816 creator A5011262525 @default.
• W2247199816 creator A5012838781 @default.
• W2247199816 creator A5057287263 @default.
• W2247199816 creator A5060469120 @default.
• W2247199816 creator A5075832839 @default.
• W2247199816 creator A5078038970 @default.
• W2247199816 creator A5080657419 @default.
• W2247199816 date "2009-05-20" @default.
• W2247199816 modified "2023-09-25" @default.
• W2247199816 title "Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation" @default.
• W2247199816 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e14512" @default.
• W2247199816 hasPublicationYear "2009" @default.
• W2247199816 type Work @default.
• W2247199816 sameAs 2247199816 @default.
• W2247199816 citedByCount "3" @default.
• W2247199816 countsByYear W22471998162019 @default.
• W2247199816 crossrefType "journal-article" @default.
• W2247199816 hasAuthorship W2247199816A5004217603 @default.
• W2247199816 hasAuthorship W2247199816A5011262525 @default.
• W2247199816 hasAuthorship W2247199816A5012838781 @default.
• W2247199816 hasAuthorship W2247199816A5057287263 @default.
• W2247199816 hasAuthorship W2247199816A5060469120 @default.
• W2247199816 hasAuthorship W2247199816A5075832839 @default.
• W2247199816 hasAuthorship W2247199816A5078038970 @default.
• W2247199816 hasAuthorship W2247199816A5080657419 @default.
• W2247199816 hasConcept C111113717 @default.
• W2247199816 hasConcept C112705442 @default.
• W2247199816 hasConcept C121608353 @default.
• W2247199816 hasConcept C126322002 @default.
• W2247199816 hasConcept C502942594 @default.
• W2247199816 hasConcept C71924100 @default.
• W2247199816 hasConcept C98274493 @default.
• W2247199816 hasConceptScore W2247199816C111113717 @default.
• W2247199816 hasConceptScore W2247199816C112705442 @default.
• W2247199816 hasConceptScore W2247199816C121608353 @default.
• W2247199816 hasConceptScore W2247199816C126322002 @default.
• W2247199816 hasConceptScore W2247199816C502942594 @default.
• W2247199816 hasConceptScore W2247199816C71924100 @default.
• W2247199816 hasConceptScore W2247199816C98274493 @default.
• W2247199816 hasLocation W22471998161 @default.
• W2247199816 hasOpenAccess W2247199816 @default.
• W2247199816 hasPrimaryLocation W22471998161 @default.
• W2247199816 hasRelatedWork W1979928292 @default.
• W2247199816 hasRelatedWork W2007384249 @default.
• W2247199816 hasRelatedWork W2010125266 @default.
• W2247199816 hasRelatedWork W2037077206 @default.
• W2247199816 hasRelatedWork W2040661541 @default.
• W2247199816 hasRelatedWork W2076790545 @default.
• W2247199816 hasRelatedWork W2081676665 @default.
• W2247199816 hasRelatedWork W2083740330 @default.
• W2247199816 hasRelatedWork W2285403736 @default.
• W2247199816 hasRelatedWork W2338789778 @default.
• W2247199816 hasRelatedWork W2522515444 @default.
• W2247199816 hasRelatedWork W2753548604 @default.
• W2247199816 hasRelatedWork W2895696350 @default.
• W2247199816 hasRelatedWork W3011425218 @default.
• W2247199816 hasRelatedWork W3110647048 @default.
• W2247199816 hasRelatedWork W2623501111 @default.
• W2247199816 hasRelatedWork W2787390140 @default.
• W2247199816 hasRelatedWork W2835584894 @default.
• W2247199816 hasRelatedWork W3017774473 @default.
• W2247199816 hasRelatedWork W3156014147 @default.
• W2247199816 isParatext "false" @default.
• W2247199816 isRetracted "false" @default.
• W2247199816 magId "2247199816" @default.
• W2247199816 workType "article" @default.